# Abpro Holdings, Inc.: overview ABPO · OTC · CIK 1893219 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/abpo.md) · [Financials](/companies/abpo/financials.md) · [Filings](/companies/abpo/filings.md) · [Insiders](/companies/abpo/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.27)](/filings/0001213900-25-110972.md) | not reported | [(2.29)](/filings/0001213900-26-059646.md) | [(1.56)](/filings/0001213900-26-090028.md) | [(0.63)](/filings/0001213900-25-110972.md) | not reported | [(0.23)](/filings/0001213900-26-059646.md) | [(0.16)](/filings/0001213900-26-090028.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Net income: us-gaap:ProfitLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | [122](/filings/0001213900-25-032133.md) | [183](/filings/0001213900-25-032133.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(9627.9%)](/filings/0001213900-25-032133.md) | [(5421.3%)](/filings/0001213900-26-044166.md) | not reported | | Net margin | % | not reported | [2312.7%](/filings/0001193125-24-082201.md) | [(3951.9%)](/filings/0001213900-26-044166.md) | not reported | | Diluted EPS | $ per share | not reported | [(0.61)](/filings/0001213900-25-032133.md) | [(22.31)](/filings/0001213900-26-044166.md) | [(1.30)](/filings/0001213900-26-044166.md) | | Free cash flow | $k | not reported | [(7,450)](/filings/0001213900-25-032133.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Net income: us-gaap:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/abpo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) None of the funds in coverage reports a position in its latest 13F. ## Recent filings [All 251 filings](/companies/abpo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-01 | 17:56 ET | [8-K](/filings/0001213900-26-095822.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-095822 | | 2026-08-25 | 17:23 ET | [8-K](/filings/0001213900-26-093599.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-093599 | | 2026-08-14 | 16:06 ET | [10-Q](/filings/0001213900-26-090028.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090028 | | 2026-06-04 | 17:12 ET | [8-K](/filings/0001213900-26-065372.md) | 3.01 Delisting notice | 0001213900-26-065372 | | 2026-05-20 | 17:21 ET | [10-Q](/filings/0001213900-26-059646.md) | Quarterly report, period 2026-03-31 | 0001213900-26-059646 | | 2026-05-01 | 18:29 ET | [10-K/A](/filings/0001213900-26-050498.md) | Annual report, amended, period 2025-12-31 | 0001213900-26-050498 | | 2026-04-15 | 17:27 ET | [10-K](/filings/0001213900-26-044166.md) | Annual report, period 2025-12-31 | 0001213900-26-044166 | | 2026-02-20 | 16:15 ET | [8-K](/filings/0001213900-26-018819.md) | 3.01 Delisting notice | 0001213900-26-018819 | | 2026-02-11 | 16:15 ET | [8-K](/filings/0001213900-26-014903.md) | 3.01 Delisting notice; 5.02 Departure or appointment of officers or directors | 0001213900-26-014903 | | 2026-02-03 | 16:15 ET | [8-K](/filings/0001213900-26-011462.md) | 5.02 Departure or appointment of officers or directors | 0001213900-26-011462 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-044166.md), filed Apr 15, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1893219 - Tickers: ABPO, ABPWW - Exchange: OTC - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.